The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Second Cancer Risk Up to 40 Years after Treatment for Hodgkin’s Lymphoma
Open accessAbstract
BACKGROUND: Survivors of Hodgkin's lymphoma are at increased risk for treatment-related subsequent malignant neoplasms. The effect of less toxic treatments, introduced in the late 1980s, on the long-term risk of a second cancer remains unknown. METHODS: We enrolled 3905 persons in the Netherlands who had survived for at least 5 years after the initiation of treatment for Hodgkin's lymphoma. Patients had received treatment between 1965 and 2000, when they were 15 to 50 years of age. We compared the risk of a second cancer among these patients with the risk that was expected on the basis of cancer incidence in the general population. Treatment-specific risks were compared within the cohort. RESULTS: With a median follow-up of 19.1 years, 1055 second cancers were diagnosed in 908 patients, resulting in a standardized incidence ratio (SIR) of 4.6 (95% confidence interval [CI], 4.3 to 4.9) in the study cohort as compared with the general population. The risk was still elevated 35 years or more after treatment (SIR, 3.9; 95% CI, 2.8 to 5.4), and the cumulative incidence of a second cancer in the study cohort at 40 years was 48.5% (95% CI, 45.4 to 51.5). The cumulative incidence of second solid cancers did not differ according to study period (1965-1976, 1977-1988, or 1989-2000) (P=0.71 for heterogeneity). Although the risk of breast cancer was lower among patients who were treated with supradiaphragmatic-field radiotherapy not including the axilla than among those who were exposed to mantle-field irradiation (hazard ratio, 0.37; 95% CI, 0.19 to 0.72), the risk of breast cancer was not lower among patients treated in the 1989-2000 study period than among those treated in the two earlier periods. A cumulative procarbazine dose of 4.3 g or more per square meter of body-surface area (which has been associated with premature menopause) was associated with a significantly lower risk of breast cancer (hazard ratio for the comparison with no chemotherapy, 0.57; 95% CI, 0.39 to 0.84) but a higher risk of gastrointestinal cancer (hazard ratio, 2.70; 95% CI, 1.69 to 4.30). CONCLUSIONS: The risk of second solid cancers did not appear to be lower among patients treated in the most recent calendar period studied (1989-2000) than among those treated in earlier periods. The awareness of an increased risk of second cancer remains crucial for survivors of Hodgkin's lymphoma. (Funded by the Dutch Cancer Society.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Statistical Methods in Cancer Research
Breslow, N. E. (1980) · Cited by 7,332
Statistical Methods in Cancer Research. Volume II – The Design and Analysis of Cohort Studies
Juul, S. (1989) · Scandinavian Journal of Social Medicine · doi:10.1177/140349488901700214 · Cited by 3,592
Late cardiotoxicity after treatment for Hodgkin lymphoma
Aleman, B. M. P., van den Belt-Dusebout, A. W., De Bruin, M. L., van 't Veer, M. B., Baaijens, M. H. A., Boer, J. P. D., Hart, A. A. M., Klokman, W. J., Kuenen, M. A., Ouwens, G. M., et al. (2007) · Blood · doi:10.1182/blood-2006-07-034405 · Cited by 746
Self-citationBreast Cancer Following Radiotherapy and Chemotherapy Among Young Women With Hodgkin Disease
Travis, L. B., Hill, D. A., Dores, G. M., Gospodarowicz, M., van Leeuwen, F. E., Holowaty, E., Glimelius, B., Andersson, M., Wiklund, T., Lynch, C. F., et al. (2003) · JAMA · doi:10.1001/jama.290.4.465 · Cited by 666
Self-citationBhatia, S., Yasui, Y., Robison, L. L., Birch, J. M., Bogue, M. K., Diller, L., DeLaat, C., Fossati-Bellani, F., Morgan, E., Oberlin, O., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.059 · Cited by 613
Specht, L., Yahalom, J., Illidge, T., Berthelsen, A. K., Constine, L. S., Eich, H. T., Girinsky, T., Hoppe, R. T., Mauch, P., Mikhaeel, N. G., et al. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2013.05.005 · Cited by 582
Dores, G. M., Metayer, C., Curtis, R. E., Lynch, C. F., Clarke, E. A., Glimelius, B., Storm, H., Pukkala, E., van Leeuwen, F. E., Holowaty, E. J., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.038 · Cited by 565
Self-citationLung Cancer Following Chemotherapy and Radiotherapy for Hodgkin's Disease
Travis, L. B. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.3.182 · Cited by 562
Swerdlow, A. J., Barber, J. A., Hudson, G. V., Cunningham, D., Gupta, R. K., Hancock, B. W., Horwich, A., Lister, T. A., & Linch, D. C. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.3.498 · Cited by 476
Second cancer risk following Hodgkin's disease: a 20-year follow-up study.
van Leeuwen, F. E., Klokman, W. J., Hagenbeek, A., Noyon, R., van den Belt-Dusebout, A. W., van Kerkhoff, E. H., van Heerde, P., & Somers, R. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.2.312 · Cited by 443
Self-citationvan Leeuwen, F. E., Klokman, W. J., Veer, M. B. V., Hagenbeek, A., Krol, A. D. G., Vetter, U. A. O., Schaapveld, M., van Heerde, P., Burgers, J. M. V., Somers, R., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.3.487 · Cited by 436
Self-citationNg, A. K., Bernardo, M. V. P., Weller, E., Backstrand, K., Silver, B., Marcus, K. C., Tarbell, N. J., Stevenson, M. A., Friedberg, J. W., & Mauch, P. M. (2002) · Blood · doi:10.1182/blood-2002-02-0634 · Cited by 433
Long-Term Solid Cancer Risk Among 5-Year Survivors of Hodgkin's Lymphoma
Hodgson, D. C., Gilbert, E. S., Dores, G. M., Schonfeld, S. J., Lynch, C. F., Storm, H., Hall, P., Langmark, F., Pukkala, E., Andersson, M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.0936 · Cited by 351
Roles of Radiotherapy and Smoking in Lung Cancer Following Hodgkin's Disease
van Leeuwen, F. E., Klokman, W. J., Stovall, M., Hagenbeek, A., van den Belt-Dusebout, A. W., Noyon, R., Boice, J. D., Burgers, J. M. V., & Somers, R. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.20.1530 · Cited by 234
Self-citationSecond Cancer Risk After Chemotherapy for Hodgkin's Lymphoma: A Collaborative British Cohort Study
Swerdlow, A. J., Higgins, C. D., Smith, P., Cunningham, D., Hancock, B. W., Horwich, A., Hoskin, P. J., Lister, T. A., Radford, J. A., Rohatiner, A. Z. S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.8268 · Cited by 222
Swerdlow, A. J., Cooke, R., Bates, A., Cunningham, D., Falk, S. J., Gilson, D., Hancock, B. W., Harris, S. J., Horwich, A., Hoskin, P. J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.8835 · Cited by 169
Maraldo, M. V., Brodin, N. P., Aznar, M. C., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt156 · Cited by 141
Stomach Cancer Risk After Treatment for Hodgkin Lymphoma
Morton, L. M., Dores, G. M., Curtis, R. E., Lynch, C. F., Stovall, M., Hall, P. N., Gilbert, E. S., Hodgson, D. C., Storm, H. H., Johannesen, T. B., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.6832 · Cited by 114
Self-citationNg, A. K., Garber, J. E., Diller, L., Birdwell, R. L., Feng, Y., Neuberg, D. S., Silver, B., Fisher, D. C., Marcus, K. J., & Mauch, P. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.5732 · Cited by 108
Roles of Radiation Dose and Chemotherapy in the Etiology of Stomach Cancer as a Second Malignancy
van den Belt‐Dusebout, A. W., Aleman, B. M. P., Besseling, G., Bruin, M. L. D., Hauptmann, M., Veer, M. B. V., de Wit, R., Ribot, J. G., Noordijk, E. M., Kerst, J. M., et al. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.01.073 · Cited by 97
Self-citationRisk of multiple primary malignancies following treatment of Hodgkin lymphoma
van Eggermond, A. M., Schaapveld, M., Lugtenburg, P. J., Krol, A. D. G., de Boer, J. P., Zijlstra, J. M., Raemaekers, J. M. M., Kremer, L. C. M., Roesink, J. M., Louwman, M. W. J., et al. (2014) · Blood · doi:10.1182/blood-2013-10-532184 · Cited by 76
Self-citationthe England and Wales Hodgkin Lymphoma Follow-up Group, Cooke, R., Jones, M. E., Cunningham, D., Falk, S. J., Gilson, D., Hancock, B. W., Harris, S., Horwich, A., Hoskin, P., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.219 · Cited by 56
Cited by
Shapiro, C. L. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1712502 · Cited by 608
André, M. P. E., Girinsky, T., Federico, M., Reman, O., Fortpied, C., Gotti, M., Casasnovas, O., Brice, P., van der Maazen, R., Re, A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.6394 · Cited by 542
Self-citationRecent Developments in Radiotherapy
Citrin, D. E. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1608986 · Cited by 488
Hodgkin lymphoma: A review and update on recent progress
Shanbhag, S., & Ambinder, R. F. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21438 · Cited by 481
Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Eichenauer, D. A., Aleman, B. M. P., André, M., Federico, M., Hutchings, M., Illidge, T., Engert, A., & Ladetto, M. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy080 · Cited by 431
Self-citation
Metadata
- Authors
- Schaapveld, M., Aleman, B. M. P., van Eggermond, A. M., Janus, C. P. M., Krol, A. D. G., van der Maazen, R. W. M., Roesink, J., Raemaekers, J. M. M., de Boer, J. P., Zijlstra, J. M., van Imhoff, G. W., Petersen, E. J., Poortmans, P. M. P., Beijert, M., Lybeert, M. L., Mulder, I., Visser, O., Louwman, M. W. J., Krul, I. M., Lugtenburg, P. J., & van Leeuwen, F. E.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-12-24
- Volume
- 373
- Issue
- 26
- Pages
- 2499-2511
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2211631799
- Cited by
- 637
- References
- 23
- FWCI
- 41.51
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.